510 related articles for article (PubMed ID: 15067052)
1. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
2. NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells.
Slifka MK; Pagarigan RR; Whitton JL
J Immunol; 2000 Feb; 164(4):2009-15. PubMed ID: 10657652
[TBL] [Abstract][Full Text] [Related]
3. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
[TBL] [Abstract][Full Text] [Related]
4. A role for CD4+ NK1.1+ T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection.
Denkers EY; Scharton-Kersten T; Barbieri S; Caspar P; Sher A
J Exp Med; 1996 Jul; 184(1):131-9. PubMed ID: 8691126
[TBL] [Abstract][Full Text] [Related]
5. CD8+ T cells rapidly acquire NK1.1 and NK cell-associated molecules upon stimulation in vitro and in vivo.
Assarsson E; Kambayashi T; Sandberg JK; Hong S; Taniguchi M; Van Kaer L; Ljunggren HG; Chambers BJ
J Immunol; 2000 Oct; 165(7):3673-9. PubMed ID: 11034371
[TBL] [Abstract][Full Text] [Related]
6. Splenic NK1.1-negative, TCR alpha beta intermediate CD4+ T cells exist in naive NK1.1 allelic positive and negative mice, with the capacity to rapidly secrete large amounts of IL-4 and IFN-gamma upon primary TCR stimulation.
Moodycliffe AM; Maiti S; Ullrich SE
J Immunol; 1999 May; 162(9):5156-63. PubMed ID: 10227987
[TBL] [Abstract][Full Text] [Related]
7. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
8. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the phenotype and function of CD8(+), alpha / beta(+) NKT cells from tumor-bearing mice that show a natural killer cell activity and lyse multiple tumor targets.
Stremmel C; Exley M; Balk S; Hohenberger W; Kuchroo VK
Eur J Immunol; 2001 Sep; 31(9):2818-28. PubMed ID: 11536181
[TBL] [Abstract][Full Text] [Related]
10. Regulation of experimental autoimmune encephalomyelitis in the C57BL/6J mouse by NK1.1+, DX5+, alpha beta+ T cells.
Fritz RB; Zhao ML
J Immunol; 2001 Mar; 166(6):4209-15. PubMed ID: 11238673
[TBL] [Abstract][Full Text] [Related]
11. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
12. In vivo acute depletion of CD8(+) T cells before murine cytomegalovirus infection upregulated innate antiviral activity of natural killer cells.
Salem ML; Hossain MS
Int J Immunopharmacol; 2000 Sep; 22(9):707-18. PubMed ID: 10884591
[TBL] [Abstract][Full Text] [Related]
13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
14. Emergence of CD8+ T cells expressing NK cell receptors in influenza A virus-infected mice.
Kambayashi T; Assarsson E; Michaëlsson J; Berglund P; Diehl AD; Chambers BJ; Ljunggren HG
J Immunol; 2000 Nov; 165(9):4964-9. PubMed ID: 11046023
[TBL] [Abstract][Full Text] [Related]
15. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
16. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
Stober D; Jomantaite I; Schirmbeck R; Reimann J
J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
[TBL] [Abstract][Full Text] [Related]
17. A population of CD62Llow Nk1.1- CD4+ T cells that resembles NK1.1+ CD4+ T cells.
Chen H; Paul WE
Eur J Immunol; 1998 Oct; 28(10):3172-82. PubMed ID: 9808186
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses.
Wang M; Ellison CA; Gartner JG; HayGlass KT
J Immunol; 1998 Feb; 160(3):1098-105. PubMed ID: 9570522
[TBL] [Abstract][Full Text] [Related]
20. Type I interferon supports primary CD8+ T-cell responses to peptide-pulsed dendritic cells in the absence of CD4+ T-cell help.
Ontiveros F; Wilson EB; Livingstone AM
Immunology; 2011 Apr; 132(4):549-58. PubMed ID: 21255009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
